Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267466 | 0.87 | SLC6A2 (0.44) | PARP10PARP15SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24266948 | 0.82 | HPGD (0.48) | PARP10PARP15MAOAMAOBSLC6A2 | |
| SCHEMBL18722089 | 0.82 | PARP10 (0.58) | PARP10PARP15MAOAMAOBSLC6A2 | |
| SCHEMBL18617050 | 0.81 | PARP10 (0.53) | PARP10PARP15MAOAMAOB | |
| SCHEMBL1390861 | 0.80 | SLC6A2 (0.48) | PARP10PARP15SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3727211 | 0.79 | PARP10 (0.51) | PARP10PARP15MAOAMAOB | |
| SCHEMBL14553122 | 0.79 | AR (0.47) | MAOAMAOBMRGPRX4 | |
| SCHEMBL14858182 | 0.79 | PARP10 (0.50) | PARP10PARP15MAOAMAOB | |
| SCHEMBL21694070 | 0.79 | PARP10 (0.51) | PARP10PARP15MAOAMAOB | |
| SCHEMBL16255446 | 0.76 | MRGPRX4 (0.51) | MAOAMAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |